Коморбидный неврологический пациент: в фокусе метаболический синдром

Abstract

INTRODUCTION. The article discusses the problem of managing patients suffering from metabolic syndrome and chronic cerebrovascular disorders. Metabolic syndrome is an important interdisciplinary problem. Metabolic syndrome significantly increases the incidence of strokes. Systemic metabolic disorders, insulin resistance and oxidative stress, as well as large vessel damage and microangiopathy play an important role. In addition, special attention is paid to low-grade chronic inflammation, which may be associated with the patient’s age. The most important risk factor for the development of acute cerebral ischemia is the combination of components of the metabolic syndrome, in particular, the combination of insulin resistance and arterial hypertension, which increase the likelihood of developing atrial fibrillation and increase the risk of an unfavorable outcome. CONCLUSION. Cognitive impairment is quite common in metabolic syndrome. When treating cognitive impairment as part of metabolic syndrome, it is advisable to use neuroprotectors. The use of citicoline (the drug “Ronocit”) has a clinically significant effect in restoring cognitive functions and reducing the risk of developing post-infarction and post-stroke dementia in patients with metabolic syndrome. The use of various approaches to the treatment of cognitive impairment in metabolic syndrome increases the likelihood of a favorable outcome. It is recommended to use the drugs “Ronocit” and “Cocarnit®” together in the treatment of patients with a predominance of cognitive and asthenic impairments and a clinical symptom complex of diabetic polyneuropathy. KEYWORDS: comorbidity, cognitive disorders, metabolic syndrome